GlobalData on MSN
Dewpoint receives FDA orphan drug designation for DPTX3186
The ODD programme incentivises the development of medicines for conditions affecting fewer than 200,000 individuals in the US ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...
Follicle-stimulating hormone (FSH), a glycoprotein secreted by gonadotroph cells of the anterior pituitary, is classically ...
Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...
Clinical Trials Arena on MSN
Aldeyra reshuffles pipeline, culling asset despite Phase II success
Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through ...
“As a first-in-class new molecular entity, HTD1801 is an anti-inflammatory metabolic modulator (AIMM) with a dual mechanism of action, AMP kinase activation and NLRP3 inflammasome inhibition, distinct ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback